KHN939 compared with placebo for inactive thyroid eye disease in China
Tests KHN939 against placebo in Chinese adults with inactive thyroid eye disease.
Key facts
- Who runs it
- Beijing Kanghong Biological Medicine Co., Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Inactive Thyroid Eye Disease
- Status
- Not yet recruiting
- Phase
- Phase 3
- People taking part
- 117 people, planned
- Started
- Aug 2026
- Expected to end
- Jun 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- KHN939
- Placebo
- Record updated
- 23 July 2026
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (16)Hide the full registry criteria
Who can take part
- Aged 18-70 years (inclusive) at the time of signing the informed consent form (ICF), male or female
- Weight between 45 kg and 100 kg (inclusive)
- Diagnosed with moderate-to-severe inactive TED:; proptosis ≥18 mm, accompanied by at least one of the following: (a) eyelid retraction ≥2 mm; (b) moderate to severe soft tissue involvement; (c) intermittent or continuous diplopia; CAS ≤ 2 points in each eye; CAS ≤ 2 in each eye for 6 months prior to screening (based on medical records); or meets all of the following criteria for ≥ 6 months prior to screening (based on patient self-report or medical records): no progression of proptosis, no new-onset or progressive TED-related diplopia, no new-onset inflammatory TED symptoms; The time since initial TED diagnosis is ≥ 2 years and < 10 years prior to screening (documented by patient history or medical records)
- Female participants of childbearing potential must have a negative serum pregnancy test during screening and agree to use an effective method of contraception from screening until 90 days after the last dose of the study drug. (Note: Women of non-childbearing potential, defined as surgically sterile or postmenopausal, are exempt.)Male participants must agree to use birth control from screening until at least 90 days after the dose of study drug
- Able to comply with all protocol-required procedures, examinations, and symptom reporting
Who cannot take part
- Known hypersensitivity to any component of the study drug formulation, or prior hypersensitivity to any monoclonal antibodies
- Ocular conditions:; Prior or investigator-assessed diagnosis of dysthyroid optic neuropathy (DON) at screening; Corneal involvement in the study eye without improvement after appropriate treatment; Prior orbital radiotherapy or surgery for TED in the study eye (including orbital decompression, strabismus correction, eyelid correction); Requires immediate or planned ophthalmic surgical intervention during the study period; Has any pre-existing ocular condition (e.g., high myopia, anticipated cataract surgery) that, as determined by the investigator, would preclude study participation or complicate the interpretation of study results
- Prior/concomitant treatments:; Use of oral or intravenous glucocorticoids within 30 days prior to screening; Periorbital/periocular corticosteroid injection within 90 days of screening; Oral or IV non-steroidal immunosuppressants within 90 days of screening; Corticosteroid or non-steroidal immunosuppressant eye drops within 7 days of screening; Received teprotumumab or teprotumumab N01 at any time prior to screening; Received anti-CD20 antibody therapy within 12 months prior to screening; Received anti-interleukin-6 receptor (anti-IL-6R) antibody therapy within 6 months prior to screening; Received any other investigational therapy for TED at any time prior to screening (including, but not limited to, biologics targeting IGF-1R, FcRn, or TSHR); Received any other monoclonal antibody therapy within 90 days prior to screening; Need for selenium or vitamin supplementation for TED treatment from 21 days pre-dose through study end (multivitamins are permitted)
- Clinically significant ear disease, prior ear surgery, hearing impairment, or abnormal pure-tone audiometry (defined as a mean bone conduction threshold ≥25 dB at 0.5, 1, 2, 4 kHz, or ≥40 dB at any frequency)
- Positive for HBsAg with HBV-DNA >1000 IU/mL or currently receiving anti-HBV therapy; positive for HIV antibody or HCV antibody; or active syphilis
- Participation in any drug, vaccine, or device clinical trial within 3 months prior to screening, or currently within follow-up or within 5 half-lives of another study
- Any other condition deemed by the investigator as inappropriate for study participation
- Medical history/conditions:; Medical conditions that contraindicate study drug use, including: suspected or confirmed inflammatory bowel disease (IBD), coagulopathy, Cerebrovascular accident (CVA) or transient ischemic attack (TIA) within 180 days, acute myocardial infarction (MI), unstable angina, or CABG/PCI within 180 days, severe arrhythmia, or severe systemic infection; Malignancy (treated or untreated) within 5 years prior to screening, except for the following cured or non-metastatic conditions: cutaneous squamous cell carcinoma (SCC) or basal cell carcinoma (BCC), cervical or prostate carcinoma in situ (CIS), papillary thyroid carcinoma; Uncontrolled diabetes (HbA1c ≥8.0% at screening, or initiation of a new diabetes medication, or a >10% dose adjustment to an existing diabetes medication within 60 days prior to screening); Poorly controlled thyroid function: defined as FT3 or FT4 deviating ≥50% from local laboratory normal range (≥1.5×ULN or ≤0.5×LLN); Uncontrolled hypertension: defined as SBP ≥160 mmHg or DBP ≥100 mmHg; renal artery stenosis; or other evidence of clinically unstable blood pressure; 12-lead ECG with a heart rate <50 or >100 bpm and evidence of active cardiac disease; or any screening ECG abnormality that, in the investigator's opinion, confounds subsequent interpretation, particularly QTcF >450 ms in males or >470 ms in females
- Laboratory exclusions at screening:; Alanine aminotransferase (ALT) >3 × ULN; Aspartate aminotransferase (AST) >3 × ULN; Serum creatinine(Cr) ≥1.5 × ULN, or glomerular filtration rate (GFR) <30 mL/min/1.73 m² (MDRD formula)
- Proptosis at Day 1 (pre-dose) that has decreased by ≥2 mm relative to screening
- Female subjects who are pregnant or lactating
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Thyroid eye disease
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a multicenter, randomized, double-masked, placebo-controlled Phase 3 study to evaluate the efficacy, safety, immunogenicity, and population pharmacokinetic (PopPK) characteristics of KHN939 in Chinese patients with moderate-to-severe inactive thyroid eye disease (TED). Approximately 117 participants who meet the study eligibility criteria will be randomized in a 2:1 ratio (stratified by smoking status) to receive 8 infusions of KHN939 or placebo q3W.
The 2 groups in the trial
- KHN939 20 mg/kgTreatment being tested
8 infusions of KHN939 q3W for a total of 21 weeks
Treatment: KHN939
- PlaceboPlacebo, for comparison
8 infusions of placebo q3W for a total of 21 weeks
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, Randomized, Double-masked, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of KHN939 in the Treatment of Moderate-to-Severe Inactive Thyroid Eye Disease (TED) in China.
- Plain-language title
- KHN939 compared with placebo for inactive thyroid eye disease in ChinaGenerated from the registry record. The registry title is the official one.
- Criteria questions
- Built from NCT07720648, who can take part
- Record updated
- 23 July 2026